{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T15:57:35Z","timestamp":1792684655086,"version":"4.5.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,28]],"date-time":"2025-03-28T00:00:00Z","timestamp":1743120000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,3,28]],"date-time":"2025-03-28T00:00:00Z","timestamp":1743120000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Dermatol Res"],"DOI":"10.1007\/s00403-025-04174-2","type":"journal-article","created":{"date-parts":[[2025,3,30]],"date-time":"2025-03-30T17:25:33Z","timestamp":1743355533000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["The impact of biologics targeting the IL-17 and IL-23 pathways on metabolic indicators in plaque psoriasis"],"prefix":"10.1007","volume":"317","author":[{"given":"Wenzhuo","family":"Jiang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiujv","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjun","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,28]]},"reference":[{"issue":"19","key":"4174_CR1","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1001\/jama.2020.4006","volume":"323","author":"AW Armstrong","year":"2020","unstructured":"Armstrong AW, Read C (2020) Pathophysiology, clinical presentation, and treatment of psoriasis: a review [J]. JAMA 323(19):1945\u20131960","journal-title":"JAMA"},{"issue":"6","key":"4174_CR2","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1007\/s13555-021-00612-x","volume":"11","author":"A Menter","year":"2021","unstructured":"Menter A, van Voorhees AS, Hsu S (2021) Pustular psoriasis: a narrative review of recent developments in pathophysiology and therapeutic options [J]. Dermatol Ther (Heidelb) 11(6):1917\u20131929","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"5","key":"4174_CR3","first-page":"Cd011535","volume":"5","author":"E Sbidian","year":"2022","unstructured":"Sbidian E, Chaimani A, Garcia-Doval I et al (2022) Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis [J]. Cochrane Database Syst Rev 5(5):Cd011535","journal-title":"Cochrane Database Syst Rev"},{"issue":"9","key":"4174_CR4","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1007\/s13555-023-00986-0","volume":"13","author":"A Buja","year":"2023","unstructured":"Buja A, Miatton A, Cozzolino C et al (2023) The prevalent comorbidome at the onset of psoriasis diagnosis [J]. Dermatol Ther (Heidelb) 13(9):2093\u20132105","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"11","key":"4174_CR5","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1111\/jdv.18263","volume":"36","author":"L Zhang","year":"2022","unstructured":"Zhang L, Guo L, Wang L et al (2022) The efficacy and safety of tofacitinib, peficitinib, solcitinib, baricitinib, abrocitinib and deucravacitinib in plaque psoriasis - a network meta-analysis [J]. J Eur Acad Dermatol Venereol 36(11):1937\u20131946","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"4174_CR6","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1007\/s12016-018-8668-1","volume":"54","author":"C Conrad","year":"2018","unstructured":"Conrad C, Gilliet M (2018) Psoriasis: from pathogenesis to targeted therapies [J]. Clin Rev Allergy Immunol 54(1):102\u2013113","journal-title":"Clin Rev Allergy Immunol"},{"key":"4174_CR7","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.2147\/DDDT.S137588","volume":"13","author":"EJ Yang","year":"2019","unstructured":"Yang EJ, Smith MP, Ly K et al (2019) Evaluating guselkumab: an anti-IL-23 antibody for the treatment of plaque psoriasis [J]. Drug Des Devel Ther 13:1993\u20132000","journal-title":"Drug Des Devel Ther"},{"issue":"11","key":"4174_CR8","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1080\/1744666X.2020.1679625","volume":"15","author":"K Ly","year":"2019","unstructured":"Ly K, Smith MP, Thibodeaux Q et al (2019) Anti IL-17 in psoriasis [J]. Expert Rev Clin Immunol 15(11):1185\u20131194","journal-title":"Expert Rev Clin Immunol"},{"issue":"2","key":"4174_CR9","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s40257-020-00578-0","volume":"22","author":"K Yang","year":"2021","unstructured":"Yang K, Oak ASW, Elewski BE (2021) Use of IL-23 Inhibitors for the treatment of plaque psoriasis and psoriatic arthritis: a comprehensive review [J]. Am J Clin Dermatol 22(2):173\u2013192","journal-title":"Am J Clin Dermatol"},{"issue":"6","key":"4174_CR10","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1007\/s40272-021-00476-w","volume":"23","author":"HA Blair","year":"2021","unstructured":"Blair HA (2021) Secukinumab: a review in moderate to severe pediatric plaque psoriasis [J]. Paediatr Drugs 23(6):601\u2013608","journal-title":"Paediatr Drugs"},{"issue":"9","key":"4174_CR11","doi-asserted-by":"crossref","first-page":"7898","DOI":"10.3390\/ijms24097898","volume":"24","author":"SK Masenga","year":"2023","unstructured":"Masenga SK, Kabwe LS, Chakulya M et al (2023) Mechanisms of oxidative stress in metabolic syndrome [J]. Int J Mol Sci 24(9):7898","journal-title":"Int J Mol Sci"},{"issue":"12","key":"4174_CR12","doi-asserted-by":"crossref","first-page":"2707","DOI":"10.3390\/nu15122707","volume":"15","author":"NH MohamedHaris","year":"2023","unstructured":"MohamedHaris NH, Krishnasamy S, Chin KY et al (2023) Metabolic syndrome screening and nutritional status of patients with psoriasis: a scoping review [J]. Nutrients 15(12):2707","journal-title":"Nutrients"},{"issue":"3","key":"4174_CR13","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1111\/jdv.16004","volume":"34","author":"S Gerdes","year":"2020","unstructured":"Gerdes S, Pinter A, Papavassilis C et al (2020) Effects of secukinumab on metabolic and liver parameters in plaque psoriasis patients [J]. J Eur Acad Dermatol Venereol 34(3):533\u2013541","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"9","key":"4174_CR14","doi-asserted-by":"crossref","first-page":"3015","DOI":"10.3390\/nu13093015","volume":"13","author":"A Pinter","year":"2021","unstructured":"Pinter A, Schwarz P, Gerdes S et al (2021) Biologic treatment in combination with lifestyle intervention in moderate to severe plaque psoriasis and concomitant metabolic syndrome: rationale and methodology of the METABOLyx randomized controlled clinical trial [J]. Nutrients 13(9):3015","journal-title":"Nutrients"},{"issue":"16","key":"4174_CR15","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1161\/CIRCULATIONAHA.109.192644","volume":"120","author":"KG Alberti","year":"2009","unstructured":"Alberti KG, Eckel RH, Grundy SM et al (2009) Harmonizing the metabolic syndrome: a joint interim statement of the international diabetes federation task force on epidemiology and prevention; national heart, lung, and blood institute; American heart association; world heart federation; international atherosclerosis society; and international association for the study of obesity [J]. Circulation 120(16):1640\u20131645","journal-title":"Circulation"},{"issue":"10235","key":"4174_CR16","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1016\/S0140-6736(20)30564-X","volume":"395","author":"IB McInnes","year":"2020","unstructured":"McInnes IB, Behrens F, Mease PJ et al (2020) Secukinumab versus adalimumab for treatment of active psoriatic arthritis (EXCEED): a double-blind, parallel-group, randomised, active-controlled, phase 3b trial [J]. Lancet 395(10235):1496\u20131505","journal-title":"Lancet"},{"issue":"10091","key":"4174_CR17","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/S0140-6736(17)31279-5","volume":"390","author":"K Reich","year":"2017","unstructured":"Reich K, Papp KA, Blauvelt A et al (2017) Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials [J]. Lancet 390(10091):276\u2013288","journal-title":"Lancet"},{"issue":"5","key":"4174_CR18","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1007\/s13555-024-01160-w","volume":"14","author":"A Pacifico","year":"2024","unstructured":"Pacifico A, Iorizzo M, Pasch M et al (2024) Telemedicine in nail psoriasis: validation of a new tool to monitor (in-person, in-picture, and in-video) nail psoriasis severity in patients with concurrent onychophagia and onychotillomania [J]. Dermatol Ther (Heidelb) 14(5):1161\u20131172","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"10281","key":"4174_CR19","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1016\/S0140-6736(20)32549-6","volume":"397","author":"CEM Griffiths","year":"2021","unstructured":"Griffiths CEM, Armstrong AW, Gudjonsson JE et al (2021) Psoriasis [J]. Lancet 397(10281):1301\u20131315","journal-title":"Lancet"},{"issue":"91","key":"4174_CR20","first-page":"eadi848","volume":"9","author":"D Wu","year":"2024","unstructured":"Wu D, Hailer AA, Wang S et al (2024) A single-cell atlas of IL-23 inhibition in cutaneous psoriasis distinguishes clinical response [J]. Sci Immunol 9(91):eadi848","journal-title":"Sci Immunol"},{"issue":"23","key":"4174_CR21","doi-asserted-by":"crossref","first-page":"12793","DOI":"10.3390\/ijms222312793","volume":"22","author":"R Singh","year":"2021","unstructured":"Singh R, Koppu S, Perche PO et al (2021) The cytokine mediated molecular pathophysiology of psoriasis and its clinical implications [J]. Int J Mol Sci 22(23):12793","journal-title":"Int J Mol Sci"},{"issue":"Suppl 2","key":"4174_CR22","doi-asserted-by":"crossref","first-page":"11","DOI":"10.3899\/jrheum.2023-0511","volume":"50","author":"R Ag\u00fcero","year":"2023","unstructured":"Ag\u00fcero R, Woodbury MJ, Lee K et al (2023) Interleukin (IL)-17 versus IL-23 inhibitors: which is better to treat patients with moderate-to-severe psoriasis and mild psoriatic arthritis in dermatology clinics? [J]. J Rheumatol 50(Suppl 2):11\u201313","journal-title":"J Rheumatol"},{"issue":"2","key":"4174_CR23","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1056\/NEJMoa2102383","volume":"385","author":"K Reich","year":"2021","unstructured":"Reich K, Warren RB, Lebwohl M et al (2021) Bimekizumab versus secukinumab in plaque psoriasis [J]. N Engl J Med 385(2):142\u2013152","journal-title":"N Engl J Med"},{"issue":"1","key":"4174_CR24","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1111\/bjd.19341","volume":"184","author":"RB Warren","year":"2021","unstructured":"Warren RB, Blauvelt A, Poulin Y et al (2021) Efficacy and safety of risankizumab vs secukinumab in patients with moderate-to-severe (IIMMerge): results from a phase III, randomized, open-label, efficacy-assessor-blinded clinical trial. Br J Dermatol 184(1):50\u201359","journal-title":"Br J Dermatol"},{"issue":"10148","key":"4174_CR25","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/S0140-6736(18)31713-6","volume":"392","author":"KB Gordon","year":"2018","unstructured":"Gordon KB, Strober B, Lebwohl M et al (2018) Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials [J]. Lancet 392(10148):650\u2013661","journal-title":"Lancet"},{"issue":"10273","key":"4174_CR26","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/S0140-6736(21)00125-2","volume":"397","author":"K Reich","year":"2021","unstructured":"Reich K, Papp KA, Blauvelt A et al (2021) Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial [J]. Lancet 397(10273):487\u2013498","journal-title":"Lancet"},{"issue":"5","key":"4174_CR27","doi-asserted-by":"crossref","first-page":"395","DOI":"10.3109\/09546634.2015.1120852","volume":"27","author":"V di Lernia","year":"2016","unstructured":"di Lernia V, Stingeni L, Boccaletti V et al (2016) Effectiveness and safety of cyclosporine in pediatric plaque psoriasis: a multicentric retrospective analysis [J]. J Dermatolog Treat 27(5):395\u2013398","journal-title":"J Dermatolog Treat"},{"key":"4174_CR28","unstructured":"SINGH K, ARG\u00c1EZ C. CADTH Rapid Response Reports [M]. Cyclosporine for Moderate to Severe Plaque Psoriasis in Adults: A Review of Clinical Effectiveness and Safety. Ottawa (ON); Canadian Agency for Drugs and Technologies in Health Copyright \u00a9 2018 Canadian Agency for Drugs and Technologies in Health. 2018."},{"issue":"16","key":"4174_CR29","doi-asserted-by":"crossref","first-page":"5617","DOI":"10.3390\/ijms21165617","volume":"21","author":"D Holmannova","year":"2020","unstructured":"Holmannova D, Borsky P, Borska L et al (2020) Metabolic syndrome, clusterin and elafin in patients with psoriasis vulgaris [J]. Int J Mol Sci 21(16):5617","journal-title":"Int J Mol Sci"},{"issue":"6","key":"4174_CR30","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1111\/jdv.18044","volume":"36","author":"JJ Wu","year":"2022","unstructured":"Wu JJ, Kavanaugh A, Lebwohl MG et al (2022) Psoriasis and metabolic syndrome: implications for the management and treatment of psoriasis [J]. J Eur Acad Dermatol Venereol 36(6):797\u2013806","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"8","key":"4174_CR31","doi-asserted-by":"crossref","first-page":"3410","DOI":"10.1007\/s12325-023-02568-0","volume":"40","author":"A Blauvelt","year":"2023","unstructured":"Blauvelt A, Chiricozzi A, Ehst BD et al (2023) Safety of IL-23 p19 Inhibitors for the treatment of patients with moderate-to-severe plaque psoriasis: a narrative review [J]. Adv Ther 40(8):3410\u20133433","journal-title":"Adv Ther"},{"issue":"2","key":"4174_CR32","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/s13555-025-01338-w","volume":"15","author":"G Damiani","year":"2025","unstructured":"Damiani G, Pacifico A, Ricciardi S et al (2025) Management of systemic anti-psoriatic drugs in psoriasis patients with concurrent paraplegia or tetraplegia: insights from a 6-year multicenter, retrospective observational study [J]. Dermatol Ther (Heidelb) 15(2):427\u2013436","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"24","key":"4174_CR33","doi-asserted-by":"crossref","first-page":"4224","DOI":"10.3390\/cancers16244224","volume":"16","author":"LA Mateescu","year":"2024","unstructured":"Mateescu LA, Savu AP, Mutu CC et al (2024) The Intersection of Psoriasis and Neoplasia: Risk Factors, Therapeutic Approaches, and Management Strategies [J]. Cancers (Basel) 16(24):4224","journal-title":"Cancers (Basel)"},{"issue":"1","key":"4174_CR34","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1186\/s12876-020-01474-x","volume":"20","author":"J Ju","year":"2020","unstructured":"Ju J, Dai Y, Yang J et al (2020) Crohn\u2019s disease exacerbated by IL-17 inhibitors in patients with psoriasis: a case report [J]. BMC Gastroenterol 20(1):340","journal-title":"BMC Gastroenterol"},{"issue":"12","key":"4174_CR35","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1007\/s13238-018-0505-z","volume":"9","author":"Y Hou","year":"2018","unstructured":"Hou Y, Zhu L, Tian H et al (2018) IL-23-induced macrophage polarization and its pathological roles in mice with imiquimod-induced psoriasis [J]. Protein Cell 9(12):1027\u20131038","journal-title":"Protein Cell"},{"issue":"Supplement_2","key":"4174_CR36","doi-asserted-by":"crossref","first-page":"ii73","DOI":"10.1093\/ecco-jcc\/jjab190","volume":"16","author":"ZS Gottlieb","year":"2022","unstructured":"Gottlieb ZS, Sands BE (2022) Personalised Medicine with IL-23 Blockers: Myth or Reality? [J]. J Crohns Colitis 16(Supplement_2):ii73\u2013ii94","journal-title":"J Crohns Colitis"}],"container-title":["Archives of Dermatological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00403-025-04174-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00403-025-04174-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00403-025-04174-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,30]],"date-time":"2025-03-30T17:27:32Z","timestamp":1743355652000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00403-025-04174-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,28]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4174"],"URL":"https:\/\/doi.org\/10.1007\/s00403-025-04174-2","relation":{},"ISSN":["1432-069X"],"issn-type":[{"value":"1432-069X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,28]]},"assertion":[{"value":"10 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 March 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 March 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 March 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was approved by the Ethics Review Committee of The First Affiliated Hospital of Guangxi Medical University. All authors confirm that all methods are carried out in accordance with relevant guidelines and regulations.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"All patients signed an informed consent form.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Patient consent statement"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}],"article-number":"643"}}